Ten-year outcome after combined modality therapy for inflammatory breast cancer
Ten-year outcome after combined modality therapy for inflammatory breast cancer
复制标题
DOI：
10.1016/s0360-3016(02)04201-3
复制
发表时间：
2003-04-01
影响因子：
7
通讯作者：
Solin, LJ
中科院分区：
文献类型：
--
作者：
Harris, EER;Schultz, D;Solin, LJ
目的：评价炎症性乳腺癌综合治疗的远期疗效。方法与材料：对1983~1996年收治的54例炎症性乳腺癌患者的临床资料进行分析。有转移性疾病或疾病进展的患者被排除在诱导化疗之外。52例患者接受诱导化疗。52例行乳房切除术。所有患者均接受了乳房或胸壁及区域淋巴结的放射治疗。结果：5年和10年总生存率分别为56%和35%，无复发生存率分别为49%和34%。化疗后病理完全缓解的患者与未接受手术治疗的患者相比，5年和10年总生存率(分别为65%和46%)和5年和10年无复发生存率(分别为59%和50%)更好。这些患者的5年和10年无复发生存率分别为45%和27%。局部失败率在5年和10年分别为8%和19%。结论：完成多模式治疗的患者的结果与已发表的数据相比是有利的；然而，排除在诱导化疗期间进展的患者可能是这些结果的部分原因。病理完全缓解率是影响预后的重要因素。选定的炎症性乳腺癌患者具有长期生存的潜力。(C)2003年爱思唯尔科学公司。
Purpose: To evaluate the long-term outcome of combined modality therapy for inflammatory breast cancer.Methods and Materials: The data from 54 women treated between 1983 and 1996 for inflammatory breast cancer were analyzed. Patients with metastatic disease or disease progression on induction chemotherapy were excluded. Induction chemotherapy was given to 52 patients. Mastectomy was performed in 52 patients. Radiotherapy was delivered to the breast or chest wall and regional lymph nodes in all patients. The median follow-up for all patients was 5.1 years.Results: The 5- and 10-year overall survival rate was 56% and 35%, respectively; the corresponding relapse-free survival rates were 49% and 34%. Patients with a pathologic complete response after chemotherapy with or without preoperative radiotherapy had better 5- and 10-year overall survival rates (65% and 46%, respectively) and 5- and 10-year relapse-free survival rates (59% and 50%, respectively) compared with patients without a pathologic complete response. Those patients had a 5- and 10-year relapse-free survival rate of 45% and 27%, respectively. Locoregional failure at 5 and 10 years was 8% and 19%, respectively.Conclusion: The outcomes for patients completing multimodality therapy compare favorably with published data; however, the exclusion of patients with progression during induction chemotherapy may account in part for these results. The pathologic complete response rate was found to be an important prognostic factor. Selected patients with inflammatory breast cancer have the potential for long-term survival. (C) 2003 Elsevier Science Inc.